Bristol-Myers Squibb (NYSE:BMY) Shares Up 1.4%

Shares of Bristol-Myers Squibb (NYSE:BMY) were up 1.4% during mid-day trading on Wednesday . The company traded as high as $44.23 and last traded at $43.58. Approximately 4,375,857 shares were traded during trading, a decline of 72% from the average daily volume of 15,614,550 shares. The stock had previously closed at $42.98.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Barclays decreased their price objective on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a report on Wednesday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $45.00 price target on shares of Bristol-Myers Squibb in a research note on Monday. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $57.73.

Bristol-Myers Squibb Price Performance

The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock’s 50 day moving average price is $41.60 and its two-hundred day moving average price is $46.86. The stock has a market cap of $90.53 billion, a price-to-earnings ratio of -14.30, a price-to-earnings-growth ratio of 15.83 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.05 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb will post 0.54 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.37%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Institutional Investors Weigh In On Bristol-Myers Squibb

Hedge funds have recently bought and sold shares of the stock. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at $27,000. ESL Trust Services LLC acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $27,000. Accordant Advisory Group Inc acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $31,000. Pacific Capital Wealth Advisors Inc. acquired a new position in Bristol-Myers Squibb in the 4th quarter worth about $34,000. Finally, MFA Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the second quarter worth approximately $39,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.